

产品名称：恩夫韦地
产品别名：Enfuvirtide ； 恩夫韦肽

生物活性:	
Description	Enfuvirtide is an anti-HIV-1 fusion inhibitor peptide.
IC₅₀ & Target	HIV fusion[1]
In Vitro	A cell-cell fusion assay reveals that the effective concentration for achieving 50% inhibition (IC ₅₀) of Enfuvirtide is 23 ± 6 nM[2]. IFN-λs (1, 2, or 3) or the antiretrovirals (AZT, Efavirenz, Indinavir, and Enfuvirtide) significantly inhibit the expression of HIV p24 antigen and Gag gene in macrophages. IFN-λs (1, 2, or 3) also enhanced the anti-HIV (Bal) effect of AZT, Efavirenz, Indinavir, and Enfuvirtide[3].
In Vivo	Enfuvirtide has a T _{1/2} of 3.8 h[2].
Solvent&Solubility	<i>In Vitro:</i> H ₂ O : < 0.1 mg/mL (insoluble)
References	<p>[1]. Figueira TN, et al. Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. <i>Sci Rep.</i> 2017 Mar 30;7:45647.</p> <p>[2]. Cao P, et al. The improved efficacy of Sifuvirtide compared with Enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance. <i>PLoS One.</i> 2017 Feb 16;12(2):e0171567.</p> <p>[3]. Wang X, et al. IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. <i>Front Immunol.</i> 2017 Mar 6;8:210.</p>
实验参考:	
Animal Administration	For infection with the resistant HIV strains, 7-day-cultured macrophages (10 ⁵ cells/well in 96-well plates) are incubated with or without IFN-λ1, λ2, or λ3 (100 ng/mL each) and/or anti-HIV drugs: Azidothymidine (AZT) 10 pM; Efavirenz 100 pM; Indinavir 10 ⁻³ pM, and Enfuvirtide 10 nM for 24 h. Cells are then infected with different strains of HIV (6 ng p24/well) for 2 h. After washed three times with plain DMEM, cells are cultured with fresh 10% DMEM containing IFN-λs and/or antiretroviral drugs. For HIV Bal infection, culture supernatant is harvested at day 8 post infection for RT and p24 assays. Infected and untreated cells served as controls. HIV Gag gene expression in infected cells is also examined at day 8 post infection. For anti-HIV drug-resistant virus (A012 G691-6 or TC49) infection, culture supernatant is harvested for HIV p24 protein by ELISA at days 3, 5, 7, and 10 postinfection. The cell cultures are replaced with the fresh media supplemented with IFN-λ1, λ2, or λ3 and/or the antiretrovirals every 2–3 days. The culture supernatant collected at day 10 postinfection is also subjected to RT assay[3].
References	<p>[1]. Figueira TN, et al. Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. <i>Sci Rep.</i> 2017 Mar 30;7:45647.</p> <p>[2]. Cao P, et al. The improved efficacy of Sifuvirtide compared with Enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance. <i>PLoS One.</i> 2017 Feb 16;12(2):e0171567.</p> <p>[3]. Wang X, et al. IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. <i>Front Immunol.</i> 2017 Mar 6;8:210.</p>